(Q54152502)

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Taxonomy of the genus Leishmania: present and future trends and their implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Leishmaniasis reservoirs and their significance in control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

T-cell and cytokine responses in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Diagnosis of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: vertical distribution of cases in apartment blocks.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

The reemergence of visceral leishmaniasis in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Cytokines in the treatment of leishmaniasis: from studies of immunopathology to patient therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Response to Interferon‐γ plus Pentavalent Antimony in Indian Visceral Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Vaccines against leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Vaccination with DNA Encoding the Immunodominant LACK Parasite Antigen Confers Protective Immunity to Mice Infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Splenic Cytokine Responses in Indian Kala‐Azar before and after Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Evidence for a major gene controlling susceptibility to tegumentary leishmaniasis in a recently exposed Bolivian population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Laboratory tests for the diagnosis and evaluation of leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Cutaneous leishmaniasis in Guatemala: comparison of diagnostic methods

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

The natural history of cutaneous leishmaniasis in Guatemala

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Rapid and sensitive detection of Leishmania kinetoplast DNA from spleen and blood samples of kala-azar patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Diagnosis of cutaneous leishmaniasis and species discrimination of parasites by PCR and hybridization.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Rapid accurate field diagnosis of Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Trial of oral miltefosine for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Recurrent cutaneous leishmaniasis: a role for persistent parasites?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Estimation of population at risk of infection and number of cases of Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Malnutrition, age and the risk of parasitic disease: visceral leishmaniasis revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Leishmaniases of the New World: current concepts and implications for future research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Clinical spectrum of Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Recurrent lesions in human Leishmania braziliensis infection--reactivation or reinfection?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Saliva of Lutzomyia longipalpis sibling species differs in its composition and capacity to enhance leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Endemic disease and development: the leishmaniases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

A prospective study of visceral leishmaniasis in an endemic area of Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

New perspectives on a subclinical form of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Cutaneous Leishmaniasis in the Peruvian Andes: Factors Associated with Variability in Clinical Symptoms, Response to Treatment, and Parasite Isolation Rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Epidemiology of visceral leishmaniasis in northeast Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

American Cutaneous Leishmaniasis in U.S. Travelers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Epidemiology of the leishmaniases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Th1-Th2: Reliable paradigm or dangerous dogma?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Anti-leishmanial IgE antibodies: a marker of active disease in visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Interleukin 10 production correlates with pathology in human Leishmania donovani infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Recombinant interleukin 12 cures mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Resistance to Leishmania major induced by tolerance to a single antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

IL-12: initiation cytokine for cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Serodiagnosis of Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Placebo-Controlled Clinical Trial of Sodium Stibogluconate (Pentostam) versus Ketoconazole for Treating Cutaneous Leishmaniasis in Guatemala

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Practical progress and new drugs for changing patterns of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Treatment of cutaneous leishmaniasis in Colombia with dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021

Leishmania and the pathogenesis of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910178-2

7 January 2021